NCT04687059已完成2 期
A Randomised, Double-blind, Placebo-controlled Exploratory Study to Explore the Efficacy and Safety of PQ Grass 27600 SU in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen Exposure
Allergy Therapeutics14 个研究点 分布在 2 个国家目标入组 119 人开始时间: 2020年10月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 119
- 试验地点
- 14
- 主要终点
- CSMS (Combined symptom and medication score) averaged over the peak grass pollen season (GPS)
研究概览
简要总结
PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting. The study will enrol adult subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis (SAR) induced by grass pollen exposure.
详细描述
PQGrass309 is a randomised, double-blind, placebo-controlled exploratory study to explore the efficacy and safety of PQ Grass 27600 SU in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis (SAR) induced by grass pollen exposure. The study is expected to be conducted in the United States (US) and the European Union (EU). The study will enrol enough subjects to allow treatment of approximately 150 subjects.
The aim of this exploratory field study is to explore amongst others the following:
- The efficacy and safety (up to 6 months following treatment) of a cumulative dose of 27600 standardised units (SU) of PQ Grass in the treatment of grass pollen allergy.
- The expected average treatment effect on combined symptom and medication score.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed Consent
- •Capable of giving signed informed consent and demonstrates willingness to comply with the requirements and restrictions listed in the ICF and study protocol and to attend required study visits.
- •Subject who has signed and dated the ICF.
- •18 to 65 years of age inclusive, at the time of signing the ICF.
- •Sex / Contraceptive requirements:
- •Male or female.
- •Female subjects who are not of childbearing potential (defined as at least 12 months natural spontaneous amenorrhoea, or at least 6 weeks following surgical menopause) or females of childbearing potential who agree to comply with the contraceptive requirements of the study protocol.
- •Subjects and general health characteristics:
- •Good general health, as determined by the investigator, based on a medical evaluation, including medical history, physical examination, and laboratory tests. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- •Positive history of moderate to severe symptoms of seasonal allergic rhinitis and/or rhinoconjunctivitis ascribed to grass (Pooideae) pollen exposure that required repeated use of antihistamines, nasal corticosteroids, and/or leukotriene modifiers for relief of symptoms during the last 2 consecutive seasons prior to the study, confirmed by subject records.
- •Please note: Subjects with asthma may be included, but the asthma must be well controlled (according to current Global Initiative for Asthma {GINA} guidelines [GINA, 2020]).
- •A positive SPT for grass pollen (wheals [longest diameter] ≥3 mm and histamine ≥3 mm) and a negative SPT to the negative control (wheal diameter =0) at screening.
- •Grass specific IgE class ≥2 as documented by an ImmunoCAP test at screening.
- •FEV1 ≥80% of predicted, with a FEV1/FVC ratio ≥70% and (PEFR) ≥75% predicted at screening.
- •Subjects who have no suspicion or symptoms of SARS-CoV-2 infection (as assessed by the investigator) or who have had no contact with a confirmed case of COVID-19 in the past 2 weeks prior to screening and randomisation.
- •Exclusion Criteria (include amongst others):
- •Medical conditions:
- •Pregnant or lactating subject.
- •Moderate to severe allergy symptoms during the screening and treatment periods, and/or GPS caused by perennial allergens or seasonal allergens (other than grass) as verified by medical history and positive SPT.
- •Exception: screening, treatment and collection of eDiary data can be conducted outside of the pollen season(s) of concern or perennial allergies are irrelevant due to avoidance measures (e.g., cats and dog allergy).
- •Subjects with a positive SPT at US and EU sites in regions with relevant southern grass (Bahia grass, Bermuda grass or Johnson grass) exposure.
- •Moderate to severe symptoms during the 3 years prior to Visit 1 to another seasonal or perennial allergen not tested in the SPT that cannot be avoided during the study and the symptoms of which may interfere with administration of treatment and /or impact the data collected, as determined by the investigator.
- •Presence of any medical condition that may reduce the ability to survive a serious allergic reaction.
- •History of autoimmune disease including Hashimoto's thyroiditis or other immunological disorder or other diseases (including, but not limited to, malignancy, cardiovascular, gastro-intestinal, hepatic, renal, hematological, neurological, endocrine or pulmonary disease) that in the opinion of the investigator may pose a safety risk or compromise the interpretation of efficacy of the study treatment.
- •Presence of severe or uncontrolled or partly controlled asthma as defined in the GINA guidelines (GINA 2020) or asthma that requires more than a daily dose above 400 mcg of inhaled budesonide or equivalent.
- •Emergency room visit or hospitalisation for asthma in the 12 months prior to screening and randomisation or any history of a life-threatening asthma attack.
- •Presence of non-atopic rhinitis and/or rhino-sinusitis (with or without polyps).
- •Presence of nasal polyps and/or chronic sinusitis.
- •Presence of any acute or chronic ocular disorder, other than allergic conjunctivitis, which could interfere with the evaluation of CPT.
- •Eye surgery within the past 6 months.
- •Presence of any skin conditions (e.g. skin abnormalities, tattoos) which might interfere with the interpretation of the SPT results.
- •Clinical history of Type I diabetes. Subjects with well-controlled Type II diabetes will be allowed to participate at the discretion of the investigator.
- •Any acute infection (including upper respiratory tract infections in the 14 days prior to Visit 2), which in the opinion of the investigator may pose a safety risk to the subject.
- •Clinical history of severe or serious systemic reaction in response to AIT treatment in the past.
- •Clinical history of severe or life-threatening anaphylactic reactions to foods, insect venom, exercise, drugs or idiopathic anaphylaxis.
- •Clinical history of allergy, hypersensitivity or intolerance to the excipients of the IMP.
- •Tyrosine metabolism disorders, especially tyrosinemia and alkaptonuria.
- •Prior/concomitant therapy:
- •History of any allergen SIT.
- •Inability to adhere to the washout periods for Prohibited Medications/Therapies with respect to Visit 1/1a and to refrain from using the medications indicated until after Visit
- •Treatment with a preparation containing MPL (e.g., Cervarix, Shingrix, Fendrix) within 2 years prior to Visit 1 and until after completion of Visit 15 (with the exception of the IMP).
- •Unable to receive epinephrine therapy (i.e., use of epinephrine is contraindicated such as in subjects with hyperthyroidism, uncontrolled hypertension, cardiac arrhythmias, closed angle glaucoma or subjects taking other sympathomimetic).
- •Previous history of epinephrine device use.
- •β-blocker medication (including eye drops), for any indication.
- •Monoamine oxidase inhibitors and tricyclic antidepressants. (Tricyclic antidepressants should be avoided at least 2 weeks prior to screening).
- •Any previous therapy (within 12 months prior to screening) or current therapy with anti IgE (e.g., Xolair) or anti-interleukins (e.g., mepolizumab) or any other therapy with a biologic agent.
- •Unable to refrain from any vaccination (including influenza and any potential vaccine for COVID-19) during the study (unless administered more than 30 days prior to randomisation). Please note: Emergency vaccinations (e.g., tetanus due to injury) can be administered at any time.
- •Current or past therapy (within the previous 5 years) with immunosuppressant drugs or immunomodulatory biologics.
- •Other exclusions
- •Clinical history of drug or alcohol abuse which, in the investigator's opinion, could interfere with the subject's ability to participate in the study.
- 另有 7 项未显示
排除标准
- 未提供
研究组 & 干预措施
PQ Grass Standard Dosing Regimen
Experimental
Cumulative dose 27600 SU
干预措施: PQ Grass (Biological)
PQ Grass Alternative Dosing Regimen
Experimental
Cumulative dose 27600 SU
干预措施: PQ Grass (Biological)
Placebo Option 1
Placebo Comparator
Suspension for injection
干预措施: Placebo Option 1 (Drug)
Placebo option 2
Placebo Comparator
Solution for injection
干预措施: Placebo Option 2 (Drug)
结局指标
主要结局
CSMS (Combined symptom and medication score) averaged over the peak grass pollen season (GPS)
时间窗: Approximately 2-5 weeks
6 individual symptoms assessed in a 4 point severity scale (0-No symptoms to 3-Severe symptoms
次要结局
- Changes in vital signs (all subjects) at all treatment visits - Pulse rate(7 months approximately)
- CSMS averaged over the entire (or truncated) GPS(Approximately 10 weeks)
- TCS averaged over entire (or truncated) GPS(Approximately 10 weeks)
- dSS of the TCS averaged over the peak GPS and entire (or truncated) GPS(Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS)
- Daily medication score (dMS) of the CSMS averaged over the peak and entire (or truncated) GPS(Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS)
- The probability of well days and severe days during the peak and entire (or truncated) GPS.(Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS)
- Frequency of AEs leading to premature discontinuation from treatment or study(Up to 1 year)
- Changes in haematology values between screening and Visit 15 - RBC, WBC, Platelets(6 months approximately)
- Pre-GPS (Visit 12) TSS measured during CPT(Assessment Baseline (pre-GPS))
- Serum Ig responses (total IgE; grass-specific IgE and IgG4; specific IgE/total IgE and specific IgE/specific IgG4) at Visit 12 and Visit 15.(Approximately 10 weeks)
- Frequency, severity and relationship of AEs to treatment(Up to 1 year)
- Frequency of AESI(Up to 1 year)
- Changes in serum chemistry values between screening and Visit 15(6 months approximately)
- Changes in haematology values between screening and Visit 15 - Haemoglobin(6 months approximately)
- Daily symptom score (dSS) of the CSMS averaged over the peak and entire (or truncated) GPS(Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS)
- TSS during CPT, CSMS, TCS, dSS (for CSMS and TCS) and dMS (for CSMS and TCS) over the peak and entire (or truncated) GPS for subjects with a positive CPT at baseline.(Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS)
- Changes in vital signs (all subjects) at all treatment visits - Blood pressure(7 months approximately)
- Changes in vital signs (all subjects) at all treatment visits - Respiratory rate(7 months approximately)
- dMS of the TCS averaged over the peak GPS and entire (or truncated) GPS(Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS)
- RQLQ(S) measured within the GPS(Approximately 10 weeks)
- Total combined score (TCS) averaged over the peak GPS(Approximately 2-5 weeks)
- Changes in vital signs (all subjects) at all treatment visits - Body temperature(7 months approximately)
- Changes in clinical laboratory values (urinalysis) between screening and Visit 15(6 months approximately)
- Changes in PEFR (only in subjects with past or current asthma) at all treatment visits(7 months approximately)
研究者
研究点 (14)
Loading locations...
相似试验
终止
2 期
A Proof-of-concept Study to Examine QUC398 in Participants With Knee OAOsteoarthritis, KneeNCT05462990Novartis Pharmaceuticals101
已完成
3 期
Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen RhinoconjunctivitisAllergic Rhinitis Due to Grass PollensNCT00955825Stallergenes Greer473
已完成
2 期
Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for AsthmaAsthmaNCT01248975GlaxoSmithKline145
已完成
2 期
Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With MethotrexateRheumatoid ArthritisNCT02885181Gilead Sciences83
已完成
2 期
GSK2339345 Hypertussive Challenge StudyCoughNCT01899768GlaxoSmithKline16